JP2016130266A5 - - Google Patents

Download PDF

Info

Publication number
JP2016130266A5
JP2016130266A5 JP2016083344A JP2016083344A JP2016130266A5 JP 2016130266 A5 JP2016130266 A5 JP 2016130266A5 JP 2016083344 A JP2016083344 A JP 2016083344A JP 2016083344 A JP2016083344 A JP 2016083344A JP 2016130266 A5 JP2016130266 A5 JP 2016130266A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
macular degeneration
composition according
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016083344A
Other languages
English (en)
Japanese (ja)
Other versions
JP6378242B2 (ja
JP2016130266A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016130266A publication Critical patent/JP2016130266A/ja
Publication of JP2016130266A5 publication Critical patent/JP2016130266A5/ja
Application granted granted Critical
Publication of JP6378242B2 publication Critical patent/JP6378242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016083344A 2009-12-11 2016-04-19 黄斑変性の処置のための組成物および方法 Active JP6378242B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28574509P 2009-12-11 2009-12-11
US61/285,745 2009-12-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014255880A Division JP6063916B2 (ja) 2009-12-11 2014-12-18 黄斑変性の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2016130266A JP2016130266A (ja) 2016-07-21
JP2016130266A5 true JP2016130266A5 (enExample) 2016-12-01
JP6378242B2 JP6378242B2 (ja) 2018-08-22

Family

ID=44145918

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012543284A Active JP5885670B2 (ja) 2009-12-11 2010-12-09 黄斑変性の処置のための組成物および方法
JP2014255880A Active JP6063916B2 (ja) 2009-12-11 2014-12-18 黄斑変性の処置のための組成物および方法
JP2016083344A Active JP6378242B2 (ja) 2009-12-11 2016-04-19 黄斑変性の処置のための組成物および方法
JP2016245212A Pending JP2017052799A (ja) 2009-12-11 2016-12-19 黄斑変性の処置のための組成物および方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2012543284A Active JP5885670B2 (ja) 2009-12-11 2010-12-09 黄斑変性の処置のための組成物および方法
JP2014255880A Active JP6063916B2 (ja) 2009-12-11 2014-12-18 黄斑変性の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016245212A Pending JP2017052799A (ja) 2009-12-11 2016-12-19 黄斑変性の処置のための組成物および方法

Country Status (4)

Country Link
US (4) US9814701B2 (enExample)
JP (4) JP5885670B2 (enExample)
CA (1) CA2782015C (enExample)
WO (1) WO2011072141A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) * 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
AU2014209585A1 (en) * 2013-01-25 2015-07-23 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
CN118724806A (zh) * 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
KR20180116416A (ko) 2016-02-28 2018-10-24 알데이라 테라퓨틱스, 아이엔씨. 사이클로덱스트린으로의 알레르기성 안질환의 치료
CN109152774A (zh) 2016-05-09 2019-01-04 奥尔德拉医疗公司 眼部炎性病症和疾病的组合治疗
WO2018170476A1 (en) * 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
CN113056353B (zh) * 2018-09-25 2022-11-01 奥尔德拉医疗公司 用于治疗干眼病的调配物
CA3132466A1 (en) 2019-03-05 2020-09-10 Cornell University Compositions of matter with activity to remove lipofuscin from retinal cells
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2022092896A1 (ko) * 2020-10-29 2022-05-05 주식회사 피노바이오 시신경 보호 대상인 환자에게 점안제로 투여하기 위한 약학 조성물

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
SU50906A1 (ru) 1935-12-20 1936-11-30 А.И. Бурляев Веретено дл пр дильных машин
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
JPS6192592A (ja) 1984-10-12 1986-05-10 Norin Suisansyo Shokuhin Sogo Kenkyusho 分岐サイクロデキストリンの製造方法
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
US5032392A (en) 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
NZ225045A (en) 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU8942491A (en) 1990-10-22 1992-05-20 Bausch & Lomb Incorporated Method and composition for cleaning contact lenses
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
JP2746832B2 (ja) 1993-05-14 1998-05-06 大鵬薬品工業株式会社 眼局所抗アレルギー剤
GB9318431D0 (en) 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
US5767109A (en) 1993-10-20 1998-06-16 Sanchez; Robert A. Complexing urushiols
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
JP3297969B2 (ja) 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
JPH08175985A (ja) 1994-12-26 1996-07-09 Lion Corp 点眼剤
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
JP3736916B2 (ja) 1996-02-19 2006-01-18 株式会社サンコンタクトレンズ 含水性ソフトコンタクトレンズの消毒用組成物とその用途
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
EP0925282A1 (en) 1996-08-01 1999-06-30 Dowelanco 4-substituted quinoline derivatives having fungicidal activity
DK0920429T3 (da) 1996-08-06 2003-05-12 Pfizer Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
AU8330898A (en) 1997-05-02 1998-11-27 Schering Aktiengesellschaft Substituted heterocycles and their use in medicaments
JPH10306022A (ja) 1997-05-06 1998-11-17 Lion Corp 点眼剤
GB2327672A (en) 1997-07-23 1999-02-03 Merck & Co Inc 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
WO1999011643A1 (en) 1997-09-02 1999-03-11 Du Pont Pharmaceuticals Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
JP2004500308A (ja) 1998-03-12 2004-01-08 ノボ ノルディスク アクティーゼルスカブ プロテインチロシンホスアターゼのモジュレーター
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP3568108B2 (ja) 1999-07-28 2004-09-22 松下電器産業株式会社 デジタル地図の位置情報伝達方法とそれを実施する装置
US6515010B1 (en) 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
WO2001041757A1 (en) * 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6569879B2 (en) 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
JP2001318350A (ja) 2000-05-11 2001-11-16 Lion Corp コンタクトレンズ用溶液
JP4748289B2 (ja) 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
CA2416228C (en) * 2002-01-15 2010-07-13 Olsonet Communications Corporation Communication nodes for use with a wireless ad-hoc communication network
US20060014786A1 (en) 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
US20060281821A1 (en) 2003-03-14 2006-12-14 Krzysztof Palczewski Retinoid replacements and opsin agonists and methods for the use thereof
EP1621199B8 (en) * 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
JP2005132834A (ja) 2003-10-09 2005-05-26 Kyowa Hakko Kogyo Co Ltd キノリン誘導体
TWI344961B (en) 2003-10-15 2011-07-11 Ube Industries Novel indazole derivative
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
CN100558360C (zh) 2003-11-20 2009-11-11 奥特拉控股公司 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
JP2005187407A (ja) 2003-12-25 2005-07-14 Lion Corp アレルギー眼疾患用眼科組成物
US20050197292A1 (en) * 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
WO2005079774A2 (en) 2004-02-17 2005-09-01 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20070287716A1 (en) 2004-10-28 2007-12-13 Hu Essa H Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
US20100160304A1 (en) 2005-01-19 2010-06-24 Dainippon Sumitomo Pharma Co., Ltd Aromatic sulfone compound as aldosterone receptor modulator
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
CN1830964B (zh) 2005-03-11 2011-06-15 中国科学院上海药物研究所 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
JP5196130B2 (ja) 2005-12-27 2013-05-15 ライオン株式会社 ソフトコンタクトレンズ用組成物及び吸着抑制方法
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070297981A1 (en) 2006-01-25 2007-12-27 Ousler George W Iii Formulations and methods for treating dry eye
JP4466875B2 (ja) 2006-04-05 2010-05-26 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
BRPI0722382A2 (pt) 2006-04-14 2012-06-05 Prana Biotechnology Ltd compostos úteis para o tratamento de cáncer
JP5194218B2 (ja) 2006-06-05 2013-05-08 株式会社メニコンネクト 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ
EP2079699A1 (en) 2006-07-25 2009-07-22 Envivo Pharmaceuticals, Inc. Quinoline derivatives
CN101522671A (zh) 2006-08-14 2009-09-02 先灵公司 5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类,及其制备方法
NZ575171A (en) 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
TW200823187A (en) 2006-10-24 2008-06-01 Wyeth Corp Benzodioxane derivatives and uses thereof
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
US20080241256A1 (en) 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
US8490764B2 (en) 2007-05-30 2013-07-23 Margaret Simester Portable storage and changing station
TW200914437A (en) 2007-06-20 2009-04-01 Ironwood Pharmaceuticals Inc FAAH inhibitors
MX2010003667A (es) 2007-10-05 2010-09-28 Acucela Inc Compuestos alcoxi para el tratamiento de enfermedades.
US8324270B2 (en) 2008-02-11 2012-12-04 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
WO2010019606A1 (en) 2008-08-12 2010-02-18 Sirtris Pharmaceuticals, Inc. Benzoxazoles, benzthiazoles and related analogs as sirtuin modulators
BRPI0919920A2 (pt) 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
JP2012520880A (ja) 2009-03-17 2012-09-10 アーシエックス セラピューティックス, インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
US20110105450A1 (en) 2009-06-05 2011-05-05 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
WO2010148351A1 (en) 2009-06-18 2010-12-23 Cylene Pharmaceuticals, Inc. Rhodanines and related heterocycles as kinase inhibitors
EP2477594A4 (en) 2009-07-15 2013-03-13 Univ Vanderbilt ISOKETAL CATCHER AND TREATMENT OF DISEASES WITH OXIDATIVE INJURY
TWI492769B (zh) 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2011078204A1 (ja) 2009-12-24 2011-06-30 浜理薬品工業株式会社 高脂血症の予防または治療剤、および抗疲労剤
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
JP2011203665A (ja) 2010-03-26 2011-10-13 Ophtecs Corp コンタクトレンズの白濁解消用製剤及び白濁解消方法
JP2013539470A (ja) 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ, インコーポレイテッド ロルカセリンと光学活性な酸との塩
CA2816420C (en) 2010-10-29 2018-01-16 Najib Babul Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
WO2012100142A2 (en) 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
US9302013B2 (en) 2011-01-31 2016-04-05 Termira Ab Active principle for mitigating undesired medical conditions
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
JP2014530242A (ja) 2011-10-13 2014-11-17 ガデック,トーマス 皮膚疾病の処置用のケメリンc15ペプチドの局所製剤
US9817701B2 (en) 2011-12-12 2017-11-14 International Business Machines Corporation Threshold computing in a distributed computing system
US20130190500A1 (en) 2011-12-12 2013-07-25 Neuron Systems, Inc. Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene
US20130165419A1 (en) 2011-12-21 2013-06-27 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
BR112015002249A2 (pt) 2012-08-01 2017-07-04 Lewis And Clark Pharmaceuticals Inc composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
CN111135171B (zh) 2013-01-23 2023-09-08 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
JP6215354B2 (ja) 2013-01-23 2017-10-18 セムヌール ファーマシューティカルズ, インコーポレイテッド 不溶性コルチコステロイドおよび可溶性コルチコステロイドを含む医薬処方物
AU2014209585A1 (en) 2013-01-25 2015-07-23 Aldeyra Therapeutics, Inc. Novel traps in the treatment of macular degeneration
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
US9713330B1 (en) 2013-03-15 2017-07-25 Deuteria Agrochemicals, Llc Deuterium-enriched aldehydes
US20160151410A1 (en) 2013-07-02 2016-06-02 The Trustees Of Columbia University In The City Of New York Clearance of bioactive lipids from membrane structures by cyclodextrins
EP3151818A4 (en) 2014-06-04 2018-05-30 Case Western Reserve University Compositions and methods of treating diabetic retinopathy
US10736842B2 (en) 2014-06-25 2020-08-11 Synergia Bio Sciences Private Limited Pharmaceutical oil-in-water nano-emulsion
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
NO2721710T3 (enExample) 2014-08-21 2018-03-31
EP3628640B1 (en) 2014-09-02 2023-08-09 Hub Therapeutics Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
TW201628622A (zh) 2014-11-17 2016-08-16 製藥公司 Tlr抑制劑與布魯頓氏(bruton's)酪胺酸激酶抑制劑之組合
US10363231B2 (en) 2014-11-24 2019-07-30 Case Western Reserve University Compounds and methods of treating ocular disorders
US9953187B2 (en) 2014-11-25 2018-04-24 Honeywell International Inc. System and method of contextual adjustment of video fidelity to protect privacy
AU2016248376B2 (en) 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
KR20180073553A (ko) 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 알데히드 접합체 및 이의 용도
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
KR20180116416A (ko) 2016-02-28 2018-10-24 알데이라 테라퓨틱스, 아이엔씨. 사이클로덱스트린으로의 알레르기성 안질환의 치료
CN109152774A (zh) 2016-05-09 2019-01-04 奥尔德拉医疗公司 眼部炎性病症和疾病的组合治疗
US11865113B2 (en) 2016-06-06 2024-01-09 Lipidio Pharmaceuticals Inc. Methods of treating a patient afflicted with non-alcoholic steatohepatitis (NASH)
EP3500256A4 (en) 2016-08-22 2020-01-08 Aldeyra Therapeutics, Inc. ALDEHYDE TRAPPING COMPOUNDS AND USES THEREOF
AU2017317529A1 (en) 2016-08-22 2019-02-21 Aldeyra Therapeutics, Inc. Aldehyde trapping compounds and methods of use thereof
WO2018064354A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
CN109843857B (zh) 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
CA3285799A1 (en) 2016-10-12 2025-11-29 Ps Therapy, Inc. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
GB2556082A (en) 2016-11-18 2018-05-23 Warneford Healthcare Ltd Ophthalmic composition
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US10664688B2 (en) 2017-09-20 2020-05-26 Google Llc Systems and methods of detecting and responding to a visitor to a smart home environment
CN111356451A (zh) 2017-10-10 2020-06-30 奥尔德拉医疗公司 炎性病症的治疗
EP3724866A1 (en) 2017-12-14 2020-10-21 Lutron Technology Company LLC Privacy mode for a wireless audio device
WO2020018498A1 (en) 2018-07-16 2020-01-23 Aldeyra Therapeutics, Inc. Cyclodextrin formulations
US20200038392A1 (en) 2018-08-03 2020-02-06 Aldeyra Therapeutics, Inc. Topical compositions and methods of preparation and use
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
US10915995B2 (en) 2018-09-24 2021-02-09 Movidius Ltd. Methods and apparatus to generate masked images based on selective privacy and/or location tracking
CN113056353B (zh) 2018-09-25 2022-11-01 奥尔德拉医疗公司 用于治疗干眼病的调配物
JP2022503994A (ja) 2018-10-02 2022-01-12 アルデイラ セラピューティクス, インコーポレイテッド コンタクトレンズ溶液およびキット
JP2022511030A (ja) 2018-12-05 2022-01-28 アルデイラ セラピューティクス, インコーポレイテッド 注射可能な製剤
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021051003A1 (en) 2019-09-13 2021-03-18 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
US20230131929A1 (en) 2020-03-24 2023-04-27 Aldeyra Therapeutics, Inc. Quinoline compounds for treating respiratory disorders and viral infections
CA3174416A1 (en) 2020-04-13 2021-10-21 Todd Brady Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2021248031A1 (en) 2020-06-04 2021-12-09 Aldeyra Therapeutics, Inc. Dry eye disease biomarkers and their use for treatment
CN112541870A (zh) 2020-12-07 2021-03-23 北京大米科技有限公司 一种视频处理的方法、装置、可读存储介质和电子设备
WO2022150580A1 (en) 2021-01-07 2022-07-14 Aldeyra Therapeutics, Inc. Treatment of dry eye disease
CN112800947A (zh) 2021-01-27 2021-05-14 上海电气集团股份有限公司 视频监控方法、系统、电子设备及存储介质
BR112023025660A2 (pt) 2021-07-02 2024-02-27 Aldeyra Therapeutics Inc Compostos de captação de aldeído heterocíclicos e usos dos mesmos

Similar Documents

Publication Publication Date Title
JP2015057437A5 (enExample)
JOP20210001A1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
CN109415406A (zh) 羊毛甾醇前药化合物及其制备方法和应用
JP2017222697A5 (enExample)
JP2016505614A5 (enExample)
JP2016506958A5 (enExample)
JP2014521688A5 (enExample)
WO2018187553A8 (en) Fungicidal oxadiazoles
JP2017523143A5 (enExample)
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
JP2016515561A5 (enExample)
JP2018531941A5 (enExample)
JP2016507575A5 (enExample)
JP2020097577A5 (enExample)
JP2017504635A5 (enExample)
JP2016531126A5 (enExample)
CY1125198T1 (el) Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
JP2016505044A5 (enExample)
JP2015535257A5 (enExample)
JP2019535723A5 (enExample)
JP2018521056A5 (enExample)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2016503403A5 (enExample)
WO2019099564A8 (en) Novel imidazopyrimidine compounds and uses thereof